Kite Logo
Find a Treatment Center
Investor Relations
Contact Us
KiteKonnect®
Gilead Logo
  • About Us
    Our Mission Our Story Therapeutic Areas Leadership Kite Locations
  • Science & Medicine
    Our Technology Our Therapies Pipeline Trials & Expanded Access External Research Program (ERP)
  • Newsroom
    Newsroom Press Releases Company Statements Media Kit
  • Careers
    Now Hiring Careers at Kite Manufacturing Careers at Kite Early Talent Programs at Kite Culture & Benefits
  • Utility
    Contact Us KiteKonnect®
BACK TO MAIN MENU Company Statements Christi Shaw to Depart Gilead and Kite Leadership End of Q1 Kite’s Yescarta® is First Car T-Cell Therapy Recommended for Routine Use in England, United Kingdom Kite Expands Cell Therapy Manufacturing Operations in Maryland Supreme Court Denied Juno’s Appeal Request in Juno vs. Kite Case Kite Receives U.S. Food and Drug Administration (FDA) Orphan Drug Designation for KITE-222 for Acute Myeloid Leukemia Kite Launches CAR T-cell Therapy Operations in Brazil, Singapore and Saudi Arabia Kite Announces U.S. FDA Clearance of Investigational New Drug Application for Kite-363, a Dual-Targeting CAR T-Cell Therapy Candidate for Large B-Cell Lymphoma Kite’s Yescarta® (Axicabtagene Ciloleucel) Car T-Cell Therapy Now Widely Available and Publicly Funded for Patients in Australia with Four Types of Aggressive Non-Hodgkin Lymphoma Kite Announces U.S. FDA Clearance of Investigational
  • Find a Treatment Center
  • Investor Relations
Toggle Inner Dropdown
BACK TO MAIN MENU Google.com

Press Releases

Filter By Year

2023

  • March 21, 2023

    Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma

  • February 22, 2023

    Kite Completes Acquisition of Tmunity
  • February 09, 2023

    Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
  • February 02, 2023

    Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results

  • January 30, 2023

    Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

Filter By Year

Kite Logo

AREAS OF INTEREST

  • Our Mission
  • Our Technology
  • Pipeline
  • Careers at Kite

INFORMATION

  • Contact Us
  • Newsroom
  • Investors
  • KiteKonnect.com
  • Gilead.com
  • Sitemap

LEGAL

  • Privacy Policy
  • Terms and Conditions
  • Compliance Program
  • Social Media Guidelines

FOLLOW US

  • LinkedIn Logo
  • Twitter Logo

© 2017-2022 Gilead Sciences, Inc. All rights reserved.

For Kite medical information, clinical trial inquiries, adverse reactions, and product complaints contact: (844) 454-KITE (5483)